| Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease (NCT00657527) | AstraZeneca | 2001-12-01 |
| Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia (NCT00654407) | AstraZeneca | 2001-11-01 |
| Effect of Quetiapine on Negative Symptoms and Cognition (NCT00305422) | AstraZeneca | 2001-11-01 |
| Varicella Vaccination With Pulmicort (NCT00641446) | AstraZeneca | 2001-10-01 |
| Esomeprazole (NEXIUM) vs. Surgery (NCT00251927) | AstraZeneca | 2001-10-01 |
| DIabetic Retinopathy Candesartan Trials. (NCT00252720) | AstraZeneca | 2001-08-01 |
| Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD (NCT02670642) | AstraZeneca | 2001-08-01 |
| Reversal of Ventricular Remodeling With Toprol-XL (NCT00038077) | AstraZeneca | 2001-08-01 |
| DIabetic Retinopathy Candesartan Trials (NCT00252694) | AstraZeneca | 2001-08-01 |
| Pulmicort Asthma Prevention (Post-PAC) (NCT00233584) | AstraZeneca | 2001-07-01 |
| A Comparison of Seroquel vs. Risperidone in Schizophrenia (NCT00034905) | AstraZeneca | 2001-07-01 |
| Diabetic Retinopathy Candesartan Trials (NCT00252733) | AstraZeneca | 2001-06-01 |
| Quality of Life Validation in Laryngitis (NCT00641264) | AstraZeneca | 2001-05-01 |
| Open Label Trial to Assess Iressa in Prostate Cancer Patients (NCT00635856) | AstraZeneca | 2001-05-01 |
| Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs (NCT00241553) | AstraZeneca | 2001-04-01 |
| IRESSA™ (Gefitinib) in Breast Cancer Patients (NCT00632723) | AstraZeneca | 2001-04-01 |
| STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges (NCT00654537) | AstraZeneca | 2001-04-01 |
| ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00014690) | AstraZeneca | 2001-03-01 |
| Prevention of Gastric Ulcers (NCT00629512) | AstraZeneca | 2001-03-01 |
| Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs (NCT00241514) | AstraZeneca | 2001-02-01 |
| A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued (NCT00633672) | AstraZeneca | 2001-02-01 |
| A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US Only (NCT00633412) | AstraZeneca | 2001-02-01 |
| Ulcer Prevention II (NCT00629928) | AstraZeneca | 2001-02-01 |
| Budesonide / Formoterol in Treatment of Exacerbations of COPD (NCT00239278) | AstraZeneca | 2001-01-01 |
| Gynecomastia Extension Study (NCT00637182) | AstraZeneca | 2001-01-01 |
| Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs (NCT00241540) | AstraZeneca | 2001-01-01 |
| Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs (NCT00241527) | AstraZeneca | 2000-12-01 |
| PROACT - Pre-Operative Arimidex Compared To Tamoxifen (NCT00232661) | AstraZeneca | 2000-08-01 |
| Iressa Expanded Access Program (EAP) (NCT00034879) | AstraZeneca | 2000-08-01 |
| ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer (NCT00006049) | AstraZeneca | 2000-05-01 |
| ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer (NCT00006048) | AstraZeneca | 2000-05-01 |
| SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer (NCT00272740) | AstraZeneca | 2000-03-01 |
| Open-Label Extension of Other SZ1839 (Iressa) Trials (NCT00635973) | AstraZeneca | 2000-02-01 |
| Metoprolol in Acute Myocardial Infarction. A PK/PD Study (NCT01523054) | AstraZeneca | 2000-02-01 |
| Children, Perennial Allergic Rhinitis (PAR), l-t Growth (NCT00641212) | AstraZeneca | 2000-01-01 |
| Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects (NCT00654394) | AstraZeneca | 2000-01-01 |
| Long Term Open Follow-up With H376/95 vs. Warfarin (NCT00206063) | AstraZeneca | 1999-08-01 |
| OLE Study to Evaluate Safety / Efficacy of ZD4522 (NCT00654303) | AstraZeneca | 1999-08-01 |
| Efficacy Study of the Effect of Budesonide on Emphysema (NCT00232674) | AstraZeneca | 1999-07-01 |
| Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added) (NCT00634309) | AstraZeneca | 1999-06-01 |
| Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved) (NCT00634712) | AstraZeneca | 1999-06-01 |
| Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative) (NCT00634400) | AstraZeneca | 1999-03-01 |
| PreAsthmaControl (PAC) (NCT00234390) | AstraZeneca | 1998-11-01 |
| A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer (NCT00241449) | AstraZeneca | 1998-11-01 |
| TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial (NCT00227318) | AstraZeneca | 1998-07-01 |
| ATAC - Pharmacokinetics (PK) Sub-Protocol (NCT00784862) | AstraZeneca | 1998-06-01 |
| ATAC - Bone Density Sub-Protocol (NCT00784940) | AstraZeneca | 1998-06-01 |
| ATAC - Quality of Life Sub-Protocol (NCT00784680) | AstraZeneca | 1998-04-01 |
| ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years (NCT00286117) | AstraZeneca | 1998-03-01 |
| Sopran - Omeprazole Treatment Versus Surgery (NCT00256737) | AstraZeneca | 1998-01-01 |
| ATAC - Endometrial Sub-Protocol (NCT00814125) | AstraZeneca | 1997-06-01 |
| Second Line Breast Cancer Trial (NCT00635713) | AstraZeneca | 1997-05-01 |
| Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women. (NCT00287534) | AstraZeneca | 1996-11-01 |
| Inhaled Steroid Treatment as Regular Therapy in Early Asthma (NCT00641914) | AstraZeneca | 1996-10-01 |
| ATAC - Arimidex, Tamoxifen Alone or in Combination (NCT00849030) | AstraZeneca | 1996-07-01 |
| ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation. (NCT00291759) | AstraZeneca | 1996-01-01 |
| 3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer (NCT00300508) | AstraZeneca | 1996-01-01 |
| Casodex vs Placebo in Non-Metastatic Early Prostate Cancer (NCT00672282) | AstraZeneca | 1995-10-01 |
| (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer (NCT00673205) | AstraZeneca | 1995-09-01 |
| Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer (NCT00657904) | AstraZeneca | 1995-08-01 |
| Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer (NCT00846976) | AstraZeneca | 1994-12-01 |
| Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer (NCT00636259) | AstraZeneca | |
| Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours (NCT01194193) | AstraZeneca | |
| Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan (NCT03063710) | AstraZeneca | |
| An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia (NCT03501615) | AstraZeneca | |
| Anifrolumab Early Access Program (NCT04750057) | AstraZeneca | |
| An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 (NCT03259633) | AstraZeneca | |
| Cost-effectiveness Study of Symbicort as Maintenance and Reliever Therapy (SMART) (NCT00937066) | AstraZeneca | |
| Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy (NCT00888082) | AstraZeneca | |
| AZD9291 US Expanded Access Program (NCT02451852) | AstraZeneca | |
| Himalaya Early Access Program (NCT05345678) | AstraZeneca | |
| Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. (NCT03079687) | AstraZeneca | |
| Be SMART NIS, Moderate to Servere Asthma Patient Observation (NCT00514787) | AstraZeneca | |
| An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck (NCT00684385) | AstraZeneca | |
| Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment (NCT00683306) | AstraZeneca | |